Latest Breaking News On - Pablo tebas - Page 2 : vimarsana.com

Trial for Efficacy), evaluating INO-4800, its DNA vaccine candidate for COVID-19. Preliminary results show in a larger population that INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups. Findings from the Phase 2 Clinical Trial: The Phase 2 segment of the trial enrolled approximately 400 participants, 18 years of age or older, at 16 U.S. sites. Participants received either INO-4800 (1.0 mg or 2.0 mg dose) or placebo at 0 and 4 weeks (randomized 3:3:1:1). Each dose was administered by intradermal injection followed by electroporation using INOVIO s CELLECTRA ®, its proprietary smart device. Safety endpoints included systemic and local administration site reactions through 8 weeks post-dose one (or 4 weeks post-dose 2). Immunology endpoints included antigen-specific binding antibody titers, neutralization titers, and antigen-specific interferon-gamma (IFN-γ) cellular immune responses after two doses of the vaccine.

South koreaLaurentm humeauBen matonePablo tebasJeff richardsonKaneka eurogentecWalter reed army institute of researchUs department of defenseNational cancer instituteDepartment of defenseNational institute of allergyPlumbline life sciencesMelinda gates foundationCoalition for epidemic preparedness innovationsHospital of the university pennsylvaniaInternational vaccine institute